Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand
Research output: Contribution to journal › Review › Research › peer-review
Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.
| Original language | English |
|---|---|
| Journal | PET Clinics |
| Volume | 12 |
| Issue number | 3 |
| Pages (from-to) | 311-319 |
| Number of pages | 9 |
| ISSN | 1556-8598 |
| DOIs | |
| Publication status | Published - 2017 |
- Breast cancer, Invasiveness, Molecular imaging, Oncology, PET, Prognostication, Prostate cancer, Theranostics
Research areas
ID: 197803669